This cohort study compares the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with atrial fibrillation and HIV.
Source link
This cohort study compares the bleeding risks among warfarin, rivaroxaban, and apixaban users in a national US cohort with atrial fibrillation and HIV.
Source link